Motilal Oswal has initiated coverage on Indegene with a 'Buy' rating and a target price of Rs 708, suggesting a 19% upside from recent trading levels. The brokerage highlights the company's efficiency in the life sciences outsourcing sector. Investors are tracking how its integrated service model, which covers clinical and commercial operations, will support future profit growth amid evolving pharmaceutical industry needs.
Motilal Oswal has initiated coverage on Indegene with a 'Buy' rating, setting a target price of Rs 708 per share. Based on a recent trading price of approximately Rs 595, this indicates a potential upside of about 19% for investors. The brokerage's assessment focuses on Indegene’s position as a specialized service provider in the life sciences sector.
Indegene works as an outsourcing partner for large pharmaceutical companies. As these firms face pressure to manage rising research costs and strict regulatory rules, many are shifting non-core activities—such as clinical trial data management and commercial marketing operations—to specialized vendors. This structural shift allows pharmaceutical companies to focus on their primary research and development tasks while Indegene manages operational and compliance needs.
A key point highlighted by the brokerage is Indegene’s operational efficiency. The company currently generates higher revenue per employee compared to standard IT services and traditional healthcare business process outsourcing competitors. This productivity edge is expected to be a primary driver for the company's growth in the coming years.
The financial outlook for the company through fiscal years 2026 to 2028 appears positive. Motilal Oswal forecasts a 19% annual compound growth in revenue, with profit after tax projected to grow by 27%. Additionally, the brokerage expects operating leverage to push EBITDA margins to between 19% and 20% by the final quarter of fiscal year 2027. Valuation for the target price is based on a multiple of 25 times the projected earnings per share for fiscal year 2028.
While the outlook is positive, investors should remain aware of potential business risks. Like many players in the specialized outsourcing sector, Indegene faces risks related to client concentration, where a significant portion of revenue may come from a few large pharmaceutical clients. Changes in global healthcare regulations or a slowdown in pharmaceutical research spending could also impact service demand. Furthermore, maintaining high service quality while scaling operations is essential to protect profit margins.
The market will monitor the company's progress on its margin improvement goals and its ability to win and retain large-scale contracts in the evolving pharmaceutical services market. Future quarterly results and management commentary on deal execution will be key factors for shareholders to track.